{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:54:45Z","timestamp":1785326085617,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Japan Health Insurance Association"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-024-02478-7","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T17:02:59Z","timestamp":1729616579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sodium-glucose cotransporter 2 inhibitors and cardiovascular events among patients with type 2 diabetes and low-to-normal body mass index: a nationwide cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Yuichiro","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Komura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Adomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichiro","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Fukuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. Kenrik","family":"Duru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"2478_CR1","doi-asserted-by":"publisher","first-page":"108086","DOI":"10.1016\/j.diabres.2020.108086","volume":"162","author":"P Saeedi","year":"2020","unstructured":"Saeedi P, Salpea P, Karuranga S, et al. Mortality attributable to diabetes in 20\u201379 years old adults, 2019 estimates: results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 2020;162:108086.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"2478_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.eprac.2022.12.018","volume":"29","author":"K Inoue","year":"2023","unstructured":"Inoue K, Kondo N, Sato K, et al. Trends in cardiovascular risk factors by income among Japanese adults aged 30\u201349 years from 2017 to 2020: a nationwide longitudinal cohort study. Endocr Pract. 2023;29(3):185\u201392.","journal-title":"Endocr Pract"},{"key":"2478_CR3","unstructured":"National academies of sciences, engineering, and medicine, division of behavioral and social sciences and education, committee on national statistics, et al. High and rising mortality rates among working-age adults. Becker T, Majmundar MK, Harris KM, editors. Washington, D.C., DC: National Academies Press; 2021. 596 p."},{"issue":"8","key":"2478_CR4","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/jama.2021.9883","volume":"326","author":"L Wang","year":"2021","unstructured":"Wang L, Li X, Wang Z, et al. Trends in prevalence of diabetes and control of risk factors in diabetes among US adults, 1999\u20132018. JAMA. 2021;326(8):704.","journal-title":"JAMA"},{"issue":"1","key":"2478_CR5","first-page":"40","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment standards of care in diabetes\u20142023. Diabetes Care. 2022;46(1):40\u201357.","journal-title":"Diabetes Care"},{"issue":"22","key":"2478_CR6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"2478_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"7","key":"2478_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"15","key":"2478_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"16","key":"2478_CR10","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"21","key":"2478_CR11","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"key":"2478_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"issue":"15","key":"2478_CR13","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"2478_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148\u201358.","journal-title":"JAMA Cardiol"},{"issue":"10354","key":"2478_CR15","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757\u201367.","journal-title":"Lancet"},{"issue":"24","key":"2478_CR16","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"4","key":"2478_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/dom.13920","volume":"22","author":"T Ohkuma","year":"2020","unstructured":"Ohkuma T, Van Gaal L, Shaw W, et al. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. Diabetes Obes Metab. 2020;22(4):530\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2478_CR18","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/dom.14415","volume":"23","author":"Q Ji","year":"2021","unstructured":"Ji Q, Ji L, Mu Y, et al. Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: a subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia. Diabetes Obes Metab. 2021;23(8):1886\u201391.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2478_CR19","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1111\/dom.15267","volume":"25","author":"J Yu","year":"2023","unstructured":"Yu J, Sweeting AN, Gianacas C, et al. The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: insights from the CANVAS program and CREDENCE trial. Diabetes Obes Metab. 2023;25(12):3724\u20135.","journal-title":"Diabetes Obes Metab"},{"issue":"18","key":"2478_CR20","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation. 2022;146(18):1383\u2013405.","journal-title":"Circulation"},{"issue":"6","key":"2478_CR21","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632\u201344.","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"2478_CR22","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dci19-0074","volume":"43","author":"M Packer","year":"2020","unstructured":"Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43(3):508\u201311.","journal-title":"Diabetes Care"},{"key":"2478_CR23","doi-asserted-by":"crossref","unstructured":"Pandey AK, Bhatt DL, Pandey A, et al. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. Eur Heart J [Internet]. 2023 Sep 7 [cited 2023 Sep 8]; Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37674356\/","DOI":"10.1093\/eurheartj\/ehad389"},{"issue":"12","key":"2478_CR24","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.2337\/dc19-0532","volume":"42","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Sidell MA, Arterburn D, et al. Racial\/ethnic disparities in the prevalence of diabetes and prediabetes by BMI: patient outcomes research to advance learning (PORTAL) multisite cohort of adults in the US. Diabetes Care. 2019;42(12):2211\u20139.","journal-title":"Diabetes Care."},{"issue":"8","key":"2478_CR25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"2478_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/pds.4107","volume":"26","author":"S Suissa","year":"2017","unstructured":"Suissa S, Moodie EEM, Dell\u2019Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf. 2017;26(4):459\u201368.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"370","key":"2478_CR27","doi-asserted-by":"publisher","first-page":"m3342","DOI":"10.1136\/bmj.m3342","volume":"23","author":"KB Filion","year":"2020","unstructured":"Filion KB, Lix LM, Yu OH, et al. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ. 2020;23(370):m3342.","journal-title":"BMJ"},{"issue":"7","key":"2478_CR28","doi-asserted-by":"publisher","first-page":"e2962","DOI":"10.1210\/clinem\/dgac164","volume":"107","author":"PCM Au","year":"2022","unstructured":"Au PCM, Tan KCB, Cheung BMY, et al. Association between SGLT2 inhibitors vs DPP4 inhibitors and renal outcomes among patients with type 2 diabetes. J Clin Endocrinol Metab. 2022;107(7):e2962\u201370.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2478_CR29","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/dom.14082","volume":"22","author":"A Fisher","year":"2020","unstructured":"Fisher A, Fralick M, Filion KB, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: a multi-site, prevalent new-user cohort study. Diabetes Obes Metab. 2020;22(9):1648\u201358.","journal-title":"Diabetes Obes Metab"},{"issue":"16","key":"2478_CR30","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.2023.4221","volume":"329","author":"SV Wang","year":"2023","unstructured":"Wang SV, Schneeweiss S, RCT-DUPLICATE Initiative, et al. Emulation of randomized clinical trials with nonrandomized database analyses results of 32 clinical trials. JAMA. 2023;329(16):1376\u201385.","journal-title":"JAMA"},{"issue":"1","key":"2478_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69\u201379.","journal-title":"JAMA"},{"issue":"1","key":"2478_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12933-022-01474-z","volume":"21","author":"D Giugliano","year":"2022","unstructured":"Giugliano D, Longo M, Signoriello S, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovasc Diabetol. 2022;21(1):42.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2478_CR33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/jdi.13636","volume":"13","author":"R Bouchi","year":"2022","unstructured":"Bouchi R, Sugiyama T, Goto A, et al. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan. J Diabetes Investig. 2022;13(2):280\u201391.","journal-title":"J Diabetes Investig"},{"issue":"7624","key":"2478_CR34","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138.","journal-title":"BMJ"},{"key":"2478_CR35","unstructured":"Japan health insurance association. Statistics investigation [Internet]. [cited 2022 Sep 4]. Available from: https:\/\/www.kyoukaikenpo.or.jp.e.ame.hp.transer.com\/g7\/cat740\/sb7200\/1926-45139\/"},{"issue":"5","key":"2478_CR36","doi-asserted-by":"publisher","first-page":"e0286317","DOI":"10.1371\/journal.pone.0286317","volume":"18","author":"Y Mori","year":"2023","unstructured":"Mori Y, Matsushita K, Inoue K, et al. Patterns and predictors of adherence to follow-up health guidance invitations in a general health check-up program in Japan: a cohort study with an employer-sponsored insurer database. PLoS ONE. 2023;18(5):e0286317.","journal-title":"PLoS ONE"},{"issue":"3","key":"2478_CR37","doi-asserted-by":"publisher","first-page":"e235445","DOI":"10.1001\/jamahealthforum.2023.5445","volume":"5","author":"N Ishimura","year":"2024","unstructured":"Ishimura N, Inoue K, Maruyama S, et al. Income level and impaired kidney function among working adults in Japan. JAMA Health Forum. 2024;5(3):e235445.","journal-title":"JAMA Health Forum"},{"key":"2478_CR38","unstructured":"The Japanese ministry of health labour and welfare. Annual report on the implementation of general health check-up program by Japan Health Insurance Association, 2020 (Japanese) [Internet]. 2022 [cited 2022 Nov 11]. Available from: https:\/\/www.mhlw.go.jp\/content\/12400000\/000944760.xlsx"},{"issue":"12","key":"2478_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2147\/CLEP.S245555","volume":"8","author":"Y Ono","year":"2020","unstructured":"Ono Y, Taneda Y, Takeshima T, et al. Validity of claims diagnosis codes for cardiovascular diseases in diabetes patients in japanese administrative database. Clin Epidemiol. 2020;8(12):367\u201375.","journal-title":"Clin Epidemiol"},{"issue":"6","key":"2478_CR40","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"2478_CR41","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.120.051718","volume":"143","author":"JM Franklin","year":"2021","unstructured":"Franklin JM, Patorno E, Desai RJ, et al. Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE initiative. Circulation. 2021;143(10):1002\u201313.","journal-title":"Circulation"},{"issue":"11","key":"2478_CR42","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.2337\/dc20-1890","volume":"43","author":"Y Xie","year":"2020","unstructured":"Xie Y, Bowe B, Gibson AK, et al. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases. Diabetes Care. 2020;43(11):2859\u201369.","journal-title":"Diabetes Care"},{"issue":"385","key":"2478_CR43","doi-asserted-by":"publisher","first-page":"e077097","DOI":"10.1136\/bmj-2023-077097","volume":"8","author":"P Bidulka","year":"2024","unstructured":"Bidulka P, Lugo-Palacios DG, Carroll O, et al. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data. BMJ. 2024;8(385):e077097.","journal-title":"BMJ"},{"issue":"1","key":"2478_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/jdi.13321","volume":"12","author":"S Kohsaka","year":"2021","unstructured":"Kohsaka S, Takeda M, Bodeg\u00e5rd J, et al. Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan: subanalyses of the CVD-REAL 2 study. J Diabetes Investig. 2021;12(1):67\u201373.","journal-title":"J Diabetes Investig"},{"issue":"9","key":"2478_CR45","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638\u201342.","journal-title":"Diabetes Care"},{"key":"2478_CR46","unstructured":"Ministryof health, labor, and welfare, Japan. national health and nutrition survey 2019 [Internet]. [Cited 2023 Oct 12]. Available from: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/kenkou\/eiyou\/r1-houkoku_00002.html"},{"issue":"6","key":"2478_CR47","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2188\/jea.JE2008012","volume":"18","author":"SL Reynolds","year":"2008","unstructured":"Reynolds SL, Hagedorn A, Yeom J, et al. A tale of two countries\u2013the United States and Japan: are differences in health due to differences in overweight? J Epidemiol. 2008;18(6):280\u201390.","journal-title":"J Epidemiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02478-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02478-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02478-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T17:04:22Z","timestamp":1729616662000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02478-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2478"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02478-7","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have completed the ICMJE uniform disclosure format (available on request from the corresponding author).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"372"}}